Investor Presentation First Nine Months of 2022
21
Investor presentation First nine months of 2022
Novo NordiskⓇ
Novo Nordisk's opportunity is in the large unmet needs across all
therapy areas in scope.
Diabetes care
537m
people with
diabetes¹
-15%
of people in
good control²
Novo
Nordisk
Way
>764m
people with
obesity³
Obesity care
~2%
of people in medically
treated
Rare disease
Haemophilia
0.6m
people with
haemophilia4
-35%
of people being treated
Driving change to
defeat diabetes
and other serious
chronic diseases
ustainable business
16%
of global deaths
caused by
ASCVD5
>25m
people
affected by
heart failure6
Other serious
chronic diseases
>25m
people
affected by
NASH7
>70m
people
affected by AD³
1 International Diabetes Federation: Diabetes Atlas 10th edition, 2021; 2Real-world studies indicate between 30-55% of patients reach HbA₁, target <7%.e.g. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388968/, taking 42.5% in good control of treated people; 3 World
Diabetes Atlas 2022; 4 WFH annual survey 2020 (120 of 147 countries responded): Prevalence by calculating expected number of patients using 20.9 per 100.000 in haemophilia Identified patients as proxy for receiving some sort of treatment; 5 "The top 10
causes of death", WHO, 9 December 2020 (ASCVD denoted as ischaemic heart disease); "Global Public Health Burden of Heart Failure, Apr. 2017: https://pubmed.ncbi.nlm.nih.gov/28785469/; Estes C, Modeling the epidemic of non-alcoholic fatty liver disease
demonstrates an exponential increase in burden of disease, Hepatology, 2018; 8The World Alzheimer Report 2015, The Global Impact of Dementia, Alzheimer's Disease International (ADI), London.View entire presentation